BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17105418)

  • 1. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
    Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
    Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
    Quan WD; Quan FM; King LA; Walker PR
    Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
    Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
    Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
    Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
    Quan W; Knupp C; Quan F; Walker P
    Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
    Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
    Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
    Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
    Quan WD; Gagnon GA; Walker PR; Quan FM
    Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Quan FM; Perez M; Johnson E
    Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
    Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
    Quan WD; Khan N; Ramirez M; Taylor WC; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Apr; 20(2):151-4. PubMed ID: 15869448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2003 Aug; 18(4):535-8. PubMed ID: 14503947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.